Renchi Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8972510/publications.pdf

Version: 2024-02-01

		331670	361022
95	1,715	21	35
papers	citations	h-index	g-index

96	96	96	1599
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets, 2022, 33, 82-88.	2.3	17
2	Dose tapering to withdrawal stage and longâ€term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an openâ€label extension study. Journal of Thrombosis and Haemostasis, 2022, 20, 716-728.	3.8	6
3	Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia. Quality of Life Research, 2022, 31, 1533-1544.	3.1	7
4	Demographics, clinical profile and treatment landscape of patients with haemophilia B in China. Haemophilia, 2022, 28, .	2.1	3
5	Prophylactic emicizumab for hemophilia A in the Asiaâ€Pacific region: A randomized study (HAVEN 5). Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12670.	2.3	24
6	Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial. Clinical Pharmacology in Drug Development, 2022, 11, 379-387.	1.6	2
7	Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China. Haemophilia, 2022, 28, 111-118.	2.1	0
8	Healthâ€related quality of life among adults with haemophilia in China: A comparison with ageâ€matched general population. Haemophilia, 2022, 28, 776-783.	2.1	2
9	Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog) Tj ETQq1 1 0.784314 rgBT /Overlock	2.1	2
10	An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies. Haemophilia, 2021, 27, e51-e59.	2.1	15
11	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Journal of Hematology and Oncology, 2021, 14, 37.	17.0	33
12	Patients with haemophilia A with inhibitors in China: a national realâ€world analysis and followâ€up. British Journal of Haematology, 2021, 192, 900-908.	2.5	7
13	Association of FOXP3 gene polymorphisms with chronic immune thrombocytopenia in a Chinese Han population. International Journal of Laboratory Hematology, 2021, 43, 1104-1109.	1.3	6
14	Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. European Journal of Health Economics, 2021, 22, 547-557.	2.8	18
15	First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China. Medicine (United States), 2021, 100, e26077.	1.0	0
16	Pharmacokinetic, efficacy and safety evaluation of Bâ€domainâ€deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A. Haemophilia, 2021, 27, 814-822.	2.1	6
17	Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and realâ€world clinical practices. British Journal of Haematology, 2021, 194, 750-758.	2.5	2
18	Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia. Frontiers in Medicine, 2021, 8, 707998.	2.6	3

#	Article	IF	Citations
19	Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962198981.	1.7	2
20	A novel SERPINC1 frameshift mutation in two antithrombin deficiency families. International Journal of Laboratory Hematology, 2020, 42, e48-e51.	1.3	2
21	Role of bone marrowâ€derived mesenchymal stem cell defects in CD8⁺CD28^{â€“} suppressor Tâ€lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms. British Journal of Haematology, 2020, 191, 852-862.	2.5	14
22	Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies . Journal of Blood Medicine, 2020, Volume 11, 439-448.	1.7	1
23	Haemophilia care in China: Achievements in the past decade. Haemophilia, 2020, 26, 759-767.	2.1	20
24	Management of haemophilia patients in the COVIDâ€19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China. Haemophilia, 2020, 26, 1031-1037.	2.1	4
25	CD70â€silenced dendritic cells induce immune tolerance in immune thrombocytopenia patients. British Journal of Haematology, 2020, 191, 466-475.	2.5	7
26	Realâ€world analysis of haemophilia patients in China: A single centre's experience. Haemophilia, 2020, 26, 584-590.	2.1	10
27	Molecular analysis in 12 factor XI deficiency patients from China: Identification of three novel splicing mutations. Thrombosis Research, 2020, 192, 100-102.	1.7	2
28	Integrin Î²3 Deficiency Results in Hypertriglyceridemia via Disrupting LPL (Lipoprotein Lipase) Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1296-1310.	2.4	4
29	Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia. BioMed Research International, 2020, 2020, 1-8.	1.9	0
30	Outcome of CARE: a 6â€year national registry of acquired haemophilia A in China. British Journal of Haematology, 2019, 187, 653-665.	2.5	28
31	Carbapenem-resistant Enterobacteriaceae in hematological patients: Outcome of patients with Carbapenem-resistant Enterobacteriaceae infection and risk factors for progression to infection after rectal colonization. International Journal of Antimicrobial Agents, 2019, 54, 527-529.	2.5	24
32	Current and emerging treatments for immune thrombocytopenia. Expert Review of Hematology, 2019, 12, 723-732.	2.2	13
33	IP-10 and MCP-1 gene polymorphisms in Chinese patients with chronic immune thrombocytopenia. Autoimmunity, 2019, 52, 235-241.	2.6	0
34	Healthâ€related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, nonâ€interventional study (NIS). Haemophilia, 2019, 25, 382-391.	2.1	28
35	Efficacy and safety of prophylaxis with BAY 81â€8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia, 2019, 25, e153-e158.	2.1	7
36	Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China. Blood Advances, 2019, 3, 34-37.	5.2	16

#	Article	IF	Citations
37	Mutation profiling by targeted sequencing of â€œtripleâ€negativeâ€•essential thrombocythaemia patients. British Journal of Haematology, 2018, 181, 857-860.	2.5	8
38	Reduced PTEN involved in primary immune thrombocytopenia via contributing to B cell hyper-responsiveness. Molecular Immunology, 2018, 93, 144-151.	2.2	8
39	Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multiâ€•centre, nonâ€•interventional study. Haemophilia, 2018, 24, 921-929.	2.1	20
40	Abnormal Distribution and Function of Monocyte Subsets in Patients With Primary Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 786-792.	1.7	11
41	Upregulation of CD72 expression on CD19⁺CD27⁺ memory BÂcells by CD40L in primary immune thrombocytopenia. British Journal of Haematology, 2017, 178, 308-318.	2.5	13
42	The State of Skewed X Chromosome Inactivation is Retained in the Induced Pluripotent Stem Cells from a Female with Hemophilia B. Stem Cells and Development, 2017, 26, 1003-1011.	2.1	3
43	Decreased TLR4 expression on monocytes may cause regulatory T cells abnormality in patients with primary immune thrombocytopenia. Autoimmunity, 2017, 50, 283-292.	2.6	9
44	Numerical and functional defects in CD8⁺CD28^{â^'} Tâ€•suppressor lymphocytes from patients with primary immune thrombocytopenia. British Journal of Haematology, 2017, 178, 292-301.	2.5	9
45	Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare â€“ a retrospective, phase IV, non-interventional study. Current Medical Research and Opinion, 2017, 33, 1571-1578.	1.9	1
46	Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study. Current Medical Research and Opinion, 2017, 33, 1223-1230.	1.9	9
47	The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 851-858.	1.7	14
48	Increased plasma sCXCL16 levels may have a relationship with Th1/Th2 imbalance in primary immune thrombocytopenia. Cytokine, 2017, 99, 124-131.	3.2	5
49	Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatric Hematology and Oncology, 2017, 34, 146-156.	0.8	12
50	Multicentre, randomised phase <scp>III</scp> study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. British Journal of Haematology, 2017, 176, 101-110.	2.5	55
51	Longâ€•term results of splenectomy in adult chronic immune thrombocytopenia. European Journal of Haematology, 2017, 98, 235-241.	2.2	36
52	Aberrant expression of long noncoding RNA TMEVPG1 in patients with primary immune thrombocytopenia. Autoimmunity, 2016, 49, 496-502.	2.6	20
53	Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia. Autoimmunity, 2016, 49, 486-495.	2.6	5
54	Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases. Autoimmunity, 2016, 49, 50-57.	2.6	13

#	Article	IF	Citations
55	The Effect of Danazol in Primary Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 727-733.	1.7	31
56	Stromal cell-derived factor-1 rs2297630 polymorphism associated with platelet production and treatment response in Chinese patients with chronic immune thrombocytopenia. Platelets, 2016, 27, 338-343.	2.3	9
57	The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population. Platelets, 2016, 27, 26-31.	2.3	11
58	Abnormal lipid rafts related ganglioside expression and signaling in T lymphocytes in immune thrombocytopenia patients. Autoimmunity, 2016, 49, 58-68.	2.6	0
59	Acquired Hemophilia A. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 35-40.	1.7	19
60	Interleukin 35 may contribute to the loss of immunological selfâ€tolerance in patients with primary immune thrombocytopenia. British Journal of Haematology, 2015, 169, 278-285.	2.5	19
61	Prophylaxis vs. onâ€demand treatment with BAY 81â€8973, a fullâ€length plasma proteinâ€free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis, 2015, 13, 360-369.	3.8	74
62	Elevated Semaphorin 5A correlated with Th1 polarization in patients with chronic immune thrombocytopenia. Thrombosis Research, 2015, 136, 859-864.	1.7	19
63	Interleukin-7 is decreased and maybe plays a pro-inflammatory function in primary immune thrombocytopenia. Platelets, 2015, 26, 243-249.	2.3	7
64	ReducedMIR130Ais involved in primary immune thrombocytopenia via targetingTGFB1andIL18. British Journal of Haematology, 2014, 166, 767-773.	2.5	19
65	Absence of Association ofInterleukin-18Gene Polymorphisms with Primary Immune Thrombocytopenia in a Chinese Han Population. DNA and Cell Biology, 2014, 33, 537-542.	1.9	4
66	Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre. Journal of Thrombosis and Thrombolysis, 2014, 38, 92-97.	2.1	8
67	The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity, 2014, 47, 519-529.	2.6	28
68	External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (<scp>IPSET</scp>â€thrombosis) in a large cohort of <scp>C</scp>hinese patients. European Journal of Haematology, 2014, 92, 502-509.	2.2	24
69	Decreased IL-35 levels in patients with immune thrombocytopenia. Human Immunology, 2014, 75, 909-913.	2.4	21
70	The polymorphisms of T cell-specific TBX21 gene may contribute to the susceptibility of chronic immune thrombocytopenia in Chinese population. Human Immunology, 2014, 75, 129-133.	2.4	11
71	Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. Human Immunology, 2014, 75, 317-321.	2.4	25
72	Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study. Blood, 2014, 124, 1464-1464.	1.4	6

#	Article	IF	Citations
73	Distinct Molecular Abnormalities Underlie Unique Clinical Features of Essential Thrombocythemia in Children. Blood, 2014, 124, 4579-4579.	1.4	0
74	Integrin Î±IIbÎ²3-Mediated Outside-in Signaling: Brake or Amplifier of Platelet Activation?. Blood, 2014, 124, 4161-4161.	1.4	0
75	Reduced expression of <scp>MIR</scp>409â€3p in primary immune thrombocytopenia. British Journal of Haematology, 2013, 161, 128-135.	2.5	23
76	DNA Methylation and Primary Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S116-S126.	3.4	11
77	Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British Journal of Haematology, 2013, 163, 295-302.	2.5	25
78	A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. International Journal of Hematology, 2012, 96, 222-228.	1.6	77
79	Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thrombosis and Haemostasis, 2012, 107, 937-950.	3.4	37
80	Meeting the challenges of haemophilia care and patient support in China and Brazil. Haemophilia, 2012, 18, 33-38.	2.1	23
81	Hemophilic Pseudotumor in Chinese Patients: A Retrospective Single-Centered Analysis of 14 Cases. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 279-282.	1.7	28
82	Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Critical Reviews in Oncology/Hematology, 2011, 77, 172-183.	4.4	15
83	Factor VIII gene mutations profile in 148 Chinese hemophilia A subjects. European Journal of Haematology, 2010, 85, 264-272.	2.2	20
84	An FcÎ³RIIb transmembrane polymorphism in Chinese ITP patients. Platelets, 2010, 21, 479-485.	2.3	8
85	The expression of IFN-Î³, IL-4, Foxp3 and perforin genes are not correlated with DNA methylation status in patients with immune thrombocytopenic purpura. Platelets, 2010, 21, 137-143.	2.3	18
86	Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Human Immunology, 2010, 71, 586-591.	2.4	30
87	BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity, 2009, 42, 112-119.	2.6	41
88	Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Critical Reviews in Oncology/Hematology, 2008, 65, 21-31.	4.4	28
89	CD72 Polymorphism Associated with Child-Onset of Idiopathic Thrombocytopenic Purpura in Chinese Patients. Journal of Clinical Immunology, 2008, 28, 214-219.	3.8	14
90	Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic Defects.. Blood, 2007, 110, 3982-3982.	1.4	1

#	Article	IF	Citations
91	Splenectomy for Chronic Idiopathic Thrombocytopenic Purpura in Children: A Single Center Study in China. Acta Haematologica, 2006, 115, 39-45.	1.4	28
92	Abnormality of CD4+CD25+regulatory T cells in idiopathic thrombocytopenic purpura. European Journal of Haematology, 2006, 78, 061213212227003-???.	2.2	199
93	Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China. European Journal of Haematology, 2005, 75, 424-429.	2.2	18
94	Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica, 2005, 90, 914-23.	3.5	129
95	Angiogenesis in Hematologic Malignancies and Its Clinical Implications. International Journal of Hematology, 2002, 75, 246-256.	1.6	19